Global Pulmonary Disease Aerosol Delivery Devices 麻豆原创 Growth 2024-2030

Publication ID:

LPI07248006

Publication Date:

July 24, 2024

Pages:

109

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Pulmonary Disease Aerosol Delivery Devices are medical instruments designed to administer medications directly to the lungs in the form of aerosolized particles, facilitating the treatment of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. These devices include nebulizers, metered-dose inhalers (MDIs), and dry powder inhalers (DPIs), each tailored to deliver precise doses of medication efficiently. By converting liquid medication into a fine mist or aerosol, these devices enable rapid absorption through the respiratory tract, providing quick relief of symptoms and improving lung function. They are essential for managing chronic respiratory diseases, ensuring patients receive effective and targeted therapy with minimal systemic side effects.
The global Pulmonary Disease Aerosol Delivery Devices market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the 鈥淧ulmonary Disease Aerosol Delivery Devices Industry Forecast鈥� looks at past sales and reviews total world Pulmonary Disease Aerosol Delivery Devices sales in 2023, providing a comprehensive analysis by region and market sector of projected Pulmonary Disease Aerosol Delivery Devices sales for 2024 through 2030. With Pulmonary Disease Aerosol Delivery Devices sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pulmonary Disease Aerosol Delivery Devices industry.
This Insight Report provides a comprehensive analysis of the global Pulmonary Disease Aerosol Delivery Devices landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pulmonary Disease Aerosol Delivery Devices portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Pulmonary Disease Aerosol Delivery Devices market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pulmonary Disease Aerosol Delivery Devices and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pulmonary Disease Aerosol Delivery Devices.
United States market for Pulmonary Disease Aerosol Delivery Devices is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Pulmonary Disease Aerosol Delivery Devices is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Pulmonary Disease Aerosol Delivery Devices is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Pulmonary Disease Aerosol Delivery Devices players cover GlaxoSmithKline (GSK), AstraZeneca, Boehringer Ingelheim, Mylan, Viatris, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Pulmonary Disease Aerosol Delivery Devices market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Metered- dose Inhalers
Dry-powder Inhalers
Nebulizers
Segmentation by Application:
Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Cystic Fibrosis (CF)
Idiopathic Pulmonary Fibrosis (IPF)
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
GlaxoSmithKline (GSK)
AstraZeneca
Boehringer Ingelheim
Mylan
Viatris
Novartis
AptarGroup
Chiesi Farmaceutici
Koninklijke Philips
Teva Pharmaceutical Industries
Monaghan Medical
OMRON
PARI International
Vectura
H&T Presspart
Key Questions Addressed in this Report
What is the 10-year outlook for the global Pulmonary Disease Aerosol Delivery Devices market?
What factors are driving Pulmonary Disease Aerosol Delivery Devices market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Pulmonary Disease Aerosol Delivery Devices market opportunities vary by end market size?
How does Pulmonary Disease Aerosol Delivery Devices break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Pulmonary Disease Aerosol Delivery Devices Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Pulmonary Disease Aerosol Delivery Devices by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Pulmonary Disease Aerosol Delivery Devices by Country/Region, 2019, 2023 & 2030
2.2 Pulmonary Disease Aerosol Delivery Devices Segment by Type
2.2.1 Metered- dose Inhalers
2.2.2 Dry-powder Inhalers
2.2.3 Nebulizers
2.3 Pulmonary Disease Aerosol Delivery Devices Sales by Type
2.3.1 Global Pulmonary Disease Aerosol Delivery Devices Sales 麻豆原创 Share by Type (2019-2024)
2.3.2 Global Pulmonary Disease Aerosol Delivery Devices Revenue and 麻豆原创 Share by Type (2019-2024)
2.3.3 Global Pulmonary Disease Aerosol Delivery Devices Sale Price by Type (2019-2024)
2.4 Pulmonary Disease Aerosol Delivery Devices Segment by Application
2.4.1 Asthma
2.4.2 Chronic Obstructive Pulmonary Disease (COPD)
2.4.3 Cystic Fibrosis (CF)
2.4.4 Idiopathic Pulmonary Fibrosis (IPF)
2.4.5 Others
2.5 Pulmonary Disease Aerosol Delivery Devices Sales by Application
2.5.1 Global Pulmonary Disease Aerosol Delivery Devices Sale 麻豆原创 Share by Application (2019-2024)
2.5.2 Global Pulmonary Disease Aerosol Delivery Devices Revenue and 麻豆原创 Share by Application (2019-2024)
2.5.3 Global Pulmonary Disease Aerosol Delivery Devices Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global Pulmonary Disease Aerosol Delivery Devices Breakdown Data by Company
3.1.1 Global Pulmonary Disease Aerosol Delivery Devices Annual Sales by Company (2019-2024)
3.1.2 Global Pulmonary Disease Aerosol Delivery Devices Sales 麻豆原创 Share by Company (2019-2024)
3.2 Global Pulmonary Disease Aerosol Delivery Devices Annual Revenue by Company (2019-2024)
3.2.1 Global Pulmonary Disease Aerosol Delivery Devices Revenue by Company (2019-2024)
3.2.2 Global Pulmonary Disease Aerosol Delivery Devices Revenue 麻豆原创 Share by Company (2019-2024)
3.3 Global Pulmonary Disease Aerosol Delivery Devices Sale Price by Company
3.4 Key Manufacturers Pulmonary Disease Aerosol Delivery Devices Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Pulmonary Disease Aerosol Delivery Devices Product Location Distribution
3.4.2 Players Pulmonary Disease Aerosol Delivery Devices Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Pulmonary Disease Aerosol Delivery Devices by Geographic Region
4.1 World Historic Pulmonary Disease Aerosol Delivery Devices 麻豆原创 Size by Geographic Region (2019-2024)
4.1.1 Global Pulmonary Disease Aerosol Delivery Devices Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Pulmonary Disease Aerosol Delivery Devices Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Pulmonary Disease Aerosol Delivery Devices 麻豆原创 Size by Country/Region (2019-2024)
4.2.1 Global Pulmonary Disease Aerosol Delivery Devices Annual Sales by Country/Region (2019-2024)
4.2.2 Global Pulmonary Disease Aerosol Delivery Devices Annual Revenue by Country/Region (2019-2024)
4.3 Americas Pulmonary Disease Aerosol Delivery Devices Sales Growth
4.4 APAC Pulmonary Disease Aerosol Delivery Devices Sales Growth
4.5 Europe Pulmonary Disease Aerosol Delivery Devices Sales Growth
4.6 Middle East & Africa Pulmonary Disease Aerosol Delivery Devices Sales Growth
5 Americas
5.1 Americas Pulmonary Disease Aerosol Delivery Devices Sales by Country
5.1.1 Americas Pulmonary Disease Aerosol Delivery Devices Sales by Country (2019-2024)
5.1.2 Americas Pulmonary Disease Aerosol Delivery Devices Revenue by Country (2019-2024)
5.2 Americas Pulmonary Disease Aerosol Delivery Devices Sales by Type (2019-2024)
5.3 Americas Pulmonary Disease Aerosol Delivery Devices Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Pulmonary Disease Aerosol Delivery Devices Sales by Region
6.1.1 APAC Pulmonary Disease Aerosol Delivery Devices Sales by Region (2019-2024)
6.1.2 APAC Pulmonary Disease Aerosol Delivery Devices Revenue by Region (2019-2024)
6.2 APAC Pulmonary Disease Aerosol Delivery Devices Sales by Type (2019-2024)
6.3 APAC Pulmonary Disease Aerosol Delivery Devices Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Pulmonary Disease Aerosol Delivery Devices by Country
7.1.1 Europe Pulmonary Disease Aerosol Delivery Devices Sales by Country (2019-2024)
7.1.2 Europe Pulmonary Disease Aerosol Delivery Devices Revenue by Country (2019-2024)
7.2 Europe Pulmonary Disease Aerosol Delivery Devices Sales by Type (2019-2024)
7.3 Europe Pulmonary Disease Aerosol Delivery Devices Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Pulmonary Disease Aerosol Delivery Devices by Country
8.1.1 Middle East & Africa Pulmonary Disease Aerosol Delivery Devices Sales by Country (2019-2024)
8.1.2 Middle East & Africa Pulmonary Disease Aerosol Delivery Devices Revenue by Country (2019-2024)
8.2 Middle East & Africa Pulmonary Disease Aerosol Delivery Devices Sales by Type (2019-2024)
8.3 Middle East & Africa Pulmonary Disease Aerosol Delivery Devices Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Pulmonary Disease Aerosol Delivery Devices
10.3 Manufacturing Process Analysis of Pulmonary Disease Aerosol Delivery Devices
10.4 Industry Chain Structure of Pulmonary Disease Aerosol Delivery Devices
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Pulmonary Disease Aerosol Delivery Devices Distributors
11.3 Pulmonary Disease Aerosol Delivery Devices Customer
12 World Forecast Review for Pulmonary Disease Aerosol Delivery Devices by Geographic Region
12.1 Global Pulmonary Disease Aerosol Delivery Devices 麻豆原创 Size Forecast by Region
12.1.1 Global Pulmonary Disease Aerosol Delivery Devices Forecast by Region (2025-2030)
12.1.2 Global Pulmonary Disease Aerosol Delivery Devices Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Pulmonary Disease Aerosol Delivery Devices Forecast by Type (2025-2030)
12.7 Global Pulmonary Disease Aerosol Delivery Devices Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 GlaxoSmithKline (GSK)
13.1.1 GlaxoSmithKline (GSK) Company Information
13.1.2 GlaxoSmithKline (GSK) Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications
13.1.3 GlaxoSmithKline (GSK) Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 GlaxoSmithKline (GSK) Main Business Overview
13.1.5 GlaxoSmithKline (GSK) Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications
13.2.3 AstraZeneca Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 Boehringer Ingelheim
13.3.1 Boehringer Ingelheim Company Information
13.3.2 Boehringer Ingelheim Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications
13.3.3 Boehringer Ingelheim Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Boehringer Ingelheim Main Business Overview
13.3.5 Boehringer Ingelheim Latest Developments
13.4 Mylan
13.4.1 Mylan Company Information
13.4.2 Mylan Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications
13.4.3 Mylan Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Mylan Main Business Overview
13.4.5 Mylan Latest Developments
13.5 Viatris
13.5.1 Viatris Company Information
13.5.2 Viatris Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications
13.5.3 Viatris Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Viatris Main Business Overview
13.5.5 Viatris Latest Developments
13.6 Novartis
13.6.1 Novartis Company Information
13.6.2 Novartis Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications
13.6.3 Novartis Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Novartis Main Business Overview
13.6.5 Novartis Latest Developments
13.7 AptarGroup
13.7.1 AptarGroup Company Information
13.7.2 AptarGroup Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications
13.7.3 AptarGroup Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 AptarGroup Main Business Overview
13.7.5 AptarGroup Latest Developments
13.8 Chiesi Farmaceutici
13.8.1 Chiesi Farmaceutici Company Information
13.8.2 Chiesi Farmaceutici Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications
13.8.3 Chiesi Farmaceutici Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Chiesi Farmaceutici Main Business Overview
13.8.5 Chiesi Farmaceutici Latest Developments
13.9 Koninklijke Philips
13.9.1 Koninklijke Philips Company Information
13.9.2 Koninklijke Philips Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications
13.9.3 Koninklijke Philips Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Koninklijke Philips Main Business Overview
13.9.5 Koninklijke Philips Latest Developments
13.10 Teva Pharmaceutical Industries
13.10.1 Teva Pharmaceutical Industries Company Information
13.10.2 Teva Pharmaceutical Industries Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications
13.10.3 Teva Pharmaceutical Industries Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Teva Pharmaceutical Industries Main Business Overview
13.10.5 Teva Pharmaceutical Industries Latest Developments
13.11 Monaghan Medical
13.11.1 Monaghan Medical Company Information
13.11.2 Monaghan Medical Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications
13.11.3 Monaghan Medical Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Monaghan Medical Main Business Overview
13.11.5 Monaghan Medical Latest Developments
13.12 OMRON
13.12.1 OMRON Company Information
13.12.2 OMRON Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications
13.12.3 OMRON Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 OMRON Main Business Overview
13.12.5 OMRON Latest Developments
13.13 PARI International
13.13.1 PARI International Company Information
13.13.2 PARI International Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications
13.13.3 PARI International Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 PARI International Main Business Overview
13.13.5 PARI International Latest Developments
13.14 Vectura
13.14.1 Vectura Company Information
13.14.2 Vectura Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications
13.14.3 Vectura Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Vectura Main Business Overview
13.14.5 Vectura Latest Developments
13.15 H&T Presspart
13.15.1 H&T Presspart Company Information
13.15.2 H&T Presspart Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications
13.15.3 H&T Presspart Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 H&T Presspart Main Business Overview
13.15.5 H&T Presspart Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.